What Is Cagrilintide and Why Are Researchers Studying It?
Cagrilintide is a synthetic, long-acting analog of amylin, a hormone the pancreas releases alongside insulin. It is an investigational compound, not an FDA-approved medicine, and researchers study it because it acts on appetite and gastric emptying through a pathway that is separate from GLP-1 receptors. That difference is why it is most often tested together with semaglutide, in a combination called CagriSema.
This guide explains what cagrilintide is, what the published trials show, what remains unknown, and what laboratory teams should check before working with the compound. It is written for researchers and informed readers, and it is educational only. Nothing here is medical advice, and nothing here describes a treatment.
TL;DR
- Cagrilintide is a long-acting amylin analog. It is not a GLP-1 receptor agonist, and it is not FDA-approved.
- In a phase 3 program, cagrilintide alone produced an average 11.8% body weight reduction versus 2.3% with placebo at 68 weeks.
- Combined with semaglutide (CagriSema), the REDEFINE 1 trial reported 20.4% mean weight loss versus 3.0% with placebo at 68 weeks.
- Open questions include lean mass, bone density, tolerability outside trial populations, and long-term maintenance.
- For laboratory use, lot-specific COAs and correct cold-chain handling decide whether the data you generate can be trusted.
What cagrilintide is
Amylin is a peptide hormone co-secreted with insulin after meals. It signals fullness, slows how quickly the stomach empties, and helps regulate the rise in blood glucose after eating. Native amylin has a drawback for research and drug development: it is unstable and prone to forming fibrils (clumps of misfolded protein), and it clears from the body quickly.
Cagrilintide was engineered to solve those problems. Its structure is modified to reduce fibril formation and to bind albumin, which prolongs its half-life so that it can be studied on a once-weekly schedule. In short, it is amylin redesigned to stay in circulation and stay soluble.
It belongs to a class often called “weight-loss peptides,” but that label hides important differences. Semaglutide and tirzepatide act on incretin receptors. Cagrilintide acts on amylin and calcitonin receptor pathways. Researchers who lump them together tend to misread both the data and the safety profile.
How cagrilintide works: the amylin pathway
The interest in cagrilintide comes from a mechanism that complements the incretin approach. Metabolic health researchers describe it as acting directly on the brainstem to increase satiety and slow gastric emptying, through a route that does not overlap with GLP-1 receptors.
That is a meaningful point in study design. If two compounds reduce appetite through different receptors, combining them can in principle produce a larger effect than either alone. Some researchers have informally called this a “semaglutide-squared” idea, though the phrase is shorthand rather than a formal term.
Is cagrilintide a GLP-1?
No. A GLP-1 receptor agonist mimics glucagon-like peptide-1. Cagrilintide mimics amylin. It is frequently evaluated alongside GLP-1 drugs, which is why the two get confused, but the receptors, the signaling, and some of the side effect patterns differ.
What the clinical trials show
Human data on cagrilintide come mainly from Novo Nordisk’s clinical program. The numbers below are trial results in selected adult populations under medical supervision. They are not predictions for any individual, and they do not apply to unsupervised use.
| Regimen | Trial | Duration | Mean weight change | Comparator |
|---|---|---|---|---|
| Cagrilintide 2.4 mg alone | REDEFINE 1 | 68 weeks | 11.8% reduction | 2.3% placebo |
| CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) | REDEFINE 1 | 68 weeks | 20.4% reduction (treatment-policy estimand) | 3.0% placebo |
The cagrilintide monotherapy figure comes from Novo Nordisk’s September 2025 phase 3 data release. The combination figure is from the New England Journal of Medicine report on REDEFINE 1, which enrolled 3,417 adults with a BMI of 30 or higher, or 27 or higher with obesity-related complications, and no diabetes diagnosis.
The same publication reported that a higher share of participants on the combination reached the 20% or greater weight-loss threshold than those on either single agent. A separate NEJM paper reports on adults with overweight or obesity and type 2 diabetes, a population studied separately because response and risk differ.
A more recent head-to-head result
Trial results are not uniformly favorable, and a fair summary should say so. According to a regulatory status summary on Drugs.com, a February 2026 announcement reported 23% weight loss at 84 weeks with CagriSema, but the 2.4 mg/2.4 mg dose did not meet its primary endpoint of non-inferiority against tirzepatide 15 mg. A higher-dose CagriSema phase 3 trial was planned for the second half of 2026. Readers should check current registries, since this field moves quickly.
Why researchers pair it with semaglutide
Most serious cagrilintide research now sits inside the CagriSema program. The reasoning is straightforward: semaglutide works through GLP-1 receptors, cagrilintide through amylin pathways, and the combination targets complementary routes. Novo Nordisk describes CagriSema as an investigational fixed-dose injectable combining the two.
If you want the background on the incretin side, the clinical comparison of semaglutide versus tirzepatide results shows how a single-pathway approach performs, which makes the case for adding a second pathway easier to follow. For the full combination story, our own explainer on CagriSema trial results, status and safety goes deeper, and our piece on how semaglutide’s FDA labels differ clarifies why one molecule can appear under several names.
Regulatory status: where cagrilintide stands with the FDA
As of December 18, 2025, Novo Nordisk submitted a New Drug Application to the FDA for CagriSema for long-term weight management in adults with obesity or overweight and at least one comorbid condition. A submission is not an approval. Cagrilintide on its own has no FDA approval for any use, and Drugs.com listed CagriSema as not approved at its last update in February 2026.
Why many research peptides are not FDA-approved
FDA approval is expensive. It demands years of clinical trials, large safety databases, manufacturing validation, and a sponsor with the commercial backing to carry all of it. Compounds that are naturally occurring or difficult to patent often attract less of that investment, even when scientific interest in them continues. That funding gap, rather than any mystery, explains why many peptides remain in the research category while a few with strong commercial sponsors move through the approval process.
For readers, the practical meaning is simple: “not approved” signals that a compound has not completed that pathway. It does not signal that it is useless, and it does not signal that it is safe for personal use. Research-use-only compounds are for laboratory work by qualified people.
Safety and tolerability: what is known
Gastrointestinal effects such as nausea, vomiting, diarrhea, and constipation are common across metabolic peptide therapies. A 2025 network meta-analysis in the International Journal of Obesity examined these events in non-diabetic people with overweight or obesity. Its data indicate that cagrilintide did not show a statistically significant increase in diarrhea or constipation compared with controls, unlike semaglutide or tirzepatide. Symptoms were typically mild to moderate and clustered in the dose-escalation phase.
Two caveats matter:
- Trial populations are selective. Clinical obesity experts note that trials often exclude people with significant gastrointestinal disease, eating disorders, or prior bariatric surgery. A 2026 review of GLP-1-based therapies warns that use outside controlled protocols may bring different, and potentially more severe, tolerability problems, and it raises concerns about unregulated products.
- Body composition is unresolved. Rapid weight loss of 20% or more raises questions about lean muscle mass and bone density. These are active research questions in the REDEFINE program, and they are a reason that weight-loss medications are described as tools used alongside structured lifestyle changes, not as stand-alone solutions.
Anyone with a health concern or a question about a prescription should talk to a licensed physician. Peppy&Me does not sell research compounds for human consumption.
What laboratory teams should check before using cagrilintide
Because cagrilintide is a modified peptide, data quality depends on the quality of the material. Three checks matter most.
- Lot-specific certificate of analysis (COA). The COA should match the lot number on the vial. Look for purity by HPLC, mass accuracy by mass spectrometry, and independent third-party testing, not a generic template.
- Contaminant panels. Endotoxin, sterility, and heavy metals testing matter for cell-based and in-vivo work, where an endotoxin load can distort results.
- Traceability. A lot should be traceable from manufacturer to warehouse, so a surprising result can be tied back to a specific batch.
Handling is the other half. Peptides are sensitive to temperature, freeze-thaw cycles, and reconstitution technique. Keep cold-chain integrity, follow the storage guidance for each lot, and document every step. Improperly stored or untested material compromises the validity of whatever you measure, and no analysis can repair that afterward.
Our COA verification guide for semaglutide, tirzepatide and retatrutide covers the same discipline for related compounds, and this comparison of retatrutide and cagrilintide assay choices explains how the analytical approach differs between a triple-agonist and an amylin analog.
Our perspective
We see the same pattern in the questions that reach us: people read a headline number, such as 20% weight loss, and assume it describes a product they can simply buy. It does not. It describes a supervised trial of a specific regimen in a screened population, and cagrilintide remains investigational.
Our role is narrower and, we think, more useful. We supply research-use-only compounds to authorized individuals and professionals, and we try to make the evidence behind each lot easy to inspect. Every product is third-party tested for purity, mass accuracy, endotoxins, sterility, and heavy metals, and lots are traceable from manufacturer to warehouse, with COA access through QR codes. We also built a peptide glossary and a dose calculator so that researchers can handle concentrations and handling steps with fewer errors.
We would rather a researcher read the trial data critically, check the COA, and document the protocol than rely on marketing language, ours included. Orders placed before 2 PM ship the same day within the U.S., which matters when a cold-chain sample should not sit in transit longer than necessary.
— Peppy&Me
Research-grade cagrilintide from Peppy&Me
If your laboratory is working with amylin-pathway compounds, you can review our cagrilintide research listing with its lot documentation, or browse the full research compounds catalog. Access is through a private, membership-based account, with order tracking, secure checkout, and a commitment not to sell customer data. Our products are intended for laboratory research use only, for buyers aged 21 or older.
What remains unknown
The science of cagrilintide is far from settled. Several questions will shape how researchers read the next wave of data:
- Durability. How long does weight loss last, and what happens after discontinuation? Research protocols define stopping rules tightly, which is very different from unsupervised use.
- Dose. Higher-dose CagriSema trials are planned, and the dose-response relationship for cagrilintide alone is still being mapped in its dedicated program.
- Body composition. Fat mass versus lean mass and bone density need longer follow-up.
- Positioning against other agents. The February 2026 head-to-head result against tirzepatide shows that outcomes between regimens are not interchangeable and must be tested, not assumed.
- Generalizability. Findings from people without diabetes do not transfer automatically to those with it, or to groups excluded from trials.
If your work compares incretin and amylin pathways, our explainer on how retatrutide’s three targets differ from other agonists is a useful companion to the cagrilintide material above.
FAQ
What are the potential side effects of cagrilintide?
In published trials, gastrointestinal effects such as nausea were the most common, usually mild to moderate and concentrated during dose escalation. A 2025 meta-analysis found no statistically significant increase in diarrhea or constipation for cagrilintide versus controls. Trial participants were screened and monitored, so these findings do not predict outcomes outside supervised settings.
Is cagrilintide the same as semaglutide?
No. Semaglutide is a GLP-1 receptor agonist, while cagrilintide is an amylin analog acting through a different receptor pathway. They are studied together in CagriSema because their mechanisms are complementary. Semaglutide has FDA-approved labels, whereas cagrilintide does not.
Is cagrilintide FDA-approved?
No. Cagrilintide is investigational. Novo Nordisk filed an NDA for the CagriSema combination in December 2025, but a filing is not an approval, and no cagrilintide product is approved for prescription. Check the FDA and company announcements for the latest status.
Why is cagrilintide studied as a combination rather than alone?
Alone it produced an average 11.8% weight reduction at 68 weeks in phase 3, while the combination with semaglutide reached 20.4% in REDEFINE 1. Researchers want to see whether two distinct pathways produce more than either does separately. Cagrilintide now also has its own dedicated clinical program.
Sources
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity, NEJM
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes, NEJM
- CagriSema FDA Filing for Weight Loss, Novo Nordisk U.S.
- Novo Nordisk presents phase 3 data for cagrilintide, GlobeNewswire
- CagriSema FDA approval status, Drugs.com
- Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients, International Journal of Obesity
- GLP-1 receptor agonists for obesity: growing popularity met with growing questions over safety, PMC
- The next frontier in metabolic health: Cagrilintide-Semaglutide
- Semaglutide vs Tirzepatide: 6.5 Percentage Points at 72 Weeks